StageZero Life Sciences Partners with My One Medical Source and 1,000+ Medical Access Points in the USA

Aristotle and AVRT to be offered to My One Medical Source's Customer Base

TORONTO, ON / ACCESSWIRE / November 14, 2023 / StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announces it is partnering with My One Medical Source ("MOMS") to offer the StageZero suite of diagnostics and treatment protocols to MOMS' national customer base.

"MOMS has over 1,000 Medical Access Points ("MAPS") across the USA and connects providers, employers and patients with clinical laboratories. It instantly establishes a national patient service center network for StageZero and CareOncology and takes our high complexity lab and makes it into 50 State local labs with all of the attendant customer base. MOMS will actively promote StageZero's diagnostic programs" said James Howard-Tripp, Chairman and CEO of StageZero. "Coupled with the CareOncology clinical group providing clinical oversight, and via telehealth, we can cater to all 50 States and actively engage with the MAPS and their customer base, as well as draw in new patients. The new programs we are introducing continue to enhance our visibility" he further added.

Approximately 1.9 million Americans will be diagnosed with cancer this year, with more than half of them diagnosed with late stage cancer¹. Five-year survival rates for stage 3 and 4 cancer is significantly poorer than if it is diagnosed at stage 1 or 2 (eg Colorectal: 90% if found early vs 14% if found late); cost of treating late stage cancer is also 2-4 times higher than treating early stage cancer. It is critical that cancer be diagnosed as early as possible.

The US cancer screening market is $77.4 billion, with a CAGR of 7%². The economic burden associated with cancer is $150.8 billion³. Self-funded healthcare employers account for approx. 64% of all employers and employ 100 million Americans. Cancer is a key driver of their healthcare costs.^4,5,6

Sources:

1. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022. (Accessed 1.30.22); Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.